Despite SDHA and SDHB overexpression in high-risk disease, complex II inhibition did not sensitize AML cells to conventional chemotherapy with cytarabine and daunorubicin (Extended Data Fig. 7d,e). The gene discussed is SDHB; the disease is acute myeloid leukemia.